1. Clark WH Jr, Reimer RR, Greene MH, et al. Origin of familial melanomas from heritable melanocytic lesions. Arch Dermatol. 1978;114:732–738.   

2. Reimer RR, Clark WH, et al. Precursor lesions in familiar melanoma. A new genetic preneoplastic syndrome. JAMA.1978; 239(8):744–746.   

3. Greene WH, Fraumeni JF Jr. The hereditary variant of malignant melanoma. In Clark WH Jr. Human Malignant Melanoma. New York. Grune Stratton, First edition. 1979:139–166.

4. Green MH, Clark WH Jr, Tucker MA, et al. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet. 1980(letter): 2:1024.

5. Elder DE, Goldman LI, Goldman SC, et al. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer. 1980; 46:1787–94.   

6. Elder DE, B Ch, Greene MH, et al. Acquired melanocytic nevi and melanoma: the dysplastic nevus syndrome. In Ackerman AB. ed. Pathology of Malignant Melanoma. First edition. New York. Masso. 1981(chapter 11):185–215.

7. Greene MH, Clark WH Jr, Tucker MA, et al. Current concepts acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med. 1985;321(2):91–97.   

8. Elder DE. The blind men and the elephant: different views of small congenital nevi. Arch Dermatol. 1985;121:1263–1265.   

9. Clark WH Jr. The dysplastic nevus syndrome. Arch Dermatol. 1988;124:1207–1210.   

10. Clark WH, Jr.. An exchange of views regarding the dysplastic nevus controversy. In: Clark WH, Ackerman AB. Seminars in Dermatology. 1989;8(4):229–250

11. Elder DE, Clark WH, et al. The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagnos Pathol.1993;10(1):18–35.   

12. Lynch HT, Frichot BC, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet. 1978;15:352–326.   

13. Rhodes AR., Melski JW, et al. Increased intraepidermal melanocyte frequency and size in dysplastic melanocytic nevi and cutaneous melanoma. A comparative quantitative study of dysplastic melanocytic nevi, superficial spreading melanoma, nevocellular nevi, and solar lentigines. J Invest Dermatol. 1983; 80: 452–429.   

14. Kelly JW, M.B.B.S., et al. J Acad. Dermatol. 1986;14(6):1044–1052.   

15. Rhodes, AR, Weinstock MA, et al. Risk factors for cutaneous melanoma: a practical method of recognizing predisposed individuals." JAMA. 1987; 258(21): 3146–3154.   

16. Ackerman AB; An exchange of views regarding the dysplastic nevus controversy. In: Clark WH, Ackerman AB. Seminars in Dermatology 1989;8(4):229–250.

17. Knoell KA, et al. Nonpigmented dysplastic melanocytic nevi. Arch Dermatol. 1997;133(8):992–994.   

18. Kaddu S, Smolle J, et al. Melanoma with benign melanocytic nevus components: reappraisal of clinicopathological features and prognosis" Melanoma Res. 2002;12:271–278.   

19. Braun-Falco M, et al. Histopathological characteristics of small diameter melanocytic naevi: atypical nevus, dysplastic naevus or " naevus with architectural disorder and cytological atypia of melanocytes." J Clin Pathol. 2003;56(6):459–464.   

20. Dusza SW, et al. Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol. 2006;5(1):56–62.   

21. Harada K, Ackerman AB. Less than 10% of primary cutaneous melanomas, worldwide, are associated with a melanocytic nevus and that nevus usually is congenital, not "dysplastic." Dermatopathology: Practical & Conceptual. 2005;11(2) available at http://www.derm 101.com.

22. Tong KF, Murphy GF, Mihm MC, Jr. Dysplastic Nevus: A formal histogenetic precursor of malignant melanoma. In Mihm MC Jr, Murphy GF and Kaufman N. ed. Pathobiology and Recognition of Malignant Melanoma. Baltimore. United States and Canadian Academy of Pathology. First edition. 1988:10–18.